drugset / Trial / NCT04863638
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
Phase 4
Unknown
4400 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged 18-59 years old with 2-dose schedule. And subjects in the same age are randomly assigned to different immunization schedule groups.
Timeline
- Start
- 2021-04-29
- Primary completion
- 2021-12-20
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CoronaVac | Vaccine | — | — |